Sanofi Stock News

© Reuters. Sanofi logo at the company’s headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier/Files (Reuters) – Shares in Sanofi (NASDAQ:) slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the …

https://www.investing.com/news/stock-market-news/sanofi-shares-drop-on-trial-setback-for-breast-cancer-pill-2783837

(Reuters) – Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial. Results from the Phase II AMEERA-3 clinical trial, keenly awaited by Sanofi investors, showed that the drug amcenestrant, … Read More

Sanofi’s experimental cancer medicine amcenestrant failed in an intermediate clinical test for breast cancer, dealing a blow to one of the French drugmaker’s potential future blockbusters.

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in the Phase 2 AMEERA-3 trial. Resu

Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer

Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A

Sanofi (SNY) Management Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

The CIS Insulin report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a

Swedish Orphan Biovitrum AB (OTC: BIOVF ) and Sanofi SA (NASDAQ: SNY ) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated severe hemophilia A patients aged 12 and above. The study met the primary endpoint , showing clinically meaningful prevention of bleeds in … Full story available on Benzinga.com

Sanofi (SNY) and Swedish Orphan Biovitrum (Sobi) said efanesoctocog alfa (BIVV001) met the main goal of a phase 3 trial by showing clinically meaningful prevention of bleeds…

Sanofi (SNYNF, SNY) and Swedish Orphan Biovitrum AB (SWTUY.PK) reported positive topline results from the pivotal XTEND-1 phase 3 study evaluating efanesoctocog alfa in previously treated patients =12 years of age with severe hemophilia A. The company said the study met the primary endpoint, showing a clinically meaningful prevention of bleeds in people with severe hemophilia A receiving weekly prophylaxis with efanesoctocog alfa over a period of 52 weeks. The key secondary endpoint was also met, showing once-weekly efanesoctocog alfa was superior to prior prophylactic factor VIII replacement therapy.